SCHEMBL6340897

SCHEMBL6340897

CC(C(=O)NC1C2CC3CC(C2)CC1C3)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.46
HSD11B1 P28845 8/20 0.45
CYP2C9 P11712 1/20 0.41
HTT P42858 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EPHX1 P07099 2/20 0.40
HRH3 Q9Y5N1 1/20 0.39
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6338629 0.77 HSD11B1 (0.59) EPHX2HSD11B1CYP2C9ALDH1A1L3MBTL1
SCHEMBL6336061 0.75 HSD11B1 (0.52) EPHX2HSD11B1NPC1L3MBTL1EPHX1
SCHEMBL6339317 0.75 EPHX2 (0.46) EPHX2HSD11B1ALDH1A1MAPTL3MBTL1
Hydrochloric Acid SCHEMBL6339152 0.74 HSD11B1 (0.45) EPHX2HSD11B1ALDH1A1MAPTL3MBTL1
SCHEMBL20399124 0.73 USP2 (0.47) EPHX2HTTNPC1ALDH1A1MAPT
SCHEMBL1514910 0.73 USP2 (0.47) EPHX2HTTNPC1ALDH1A1MAPT
SCHEMBL72304 0.73 EPHX1 (0.53) EPHX2HSD11B1CYP2C9HTTNPC1
SCHEMBL24669979 0.72 USP2 (0.50) EPHX2HTTNPC1ALDH1A1MAPT
SCHEMBL64202 0.72 USP2 (0.50) EPHX2HTTNPC1ALDH1A1MAPT
SCHEMBL27365962 0.72 USP2 (0.50) EPHX2HTTNPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261302-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application ABBOTT LABORATORIES 2005-11-24 US disclosed
US-20050245533-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application ABBOTT LABORATORIES 2005-11-03 US disclosed
US-20050245532-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application ABBOTT LABORATORIES 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245532-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application HSD11B1, HSD17B1, HSD3B1 EPHX2 696/4885HSD11B1 1/4885CYP2C9 720/4885
US-20050245533-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application HSD11B1, HSD17B1, HSD3B1 EPHX2 676/4885HSD11B1 1/4885CYP2C9 456/4885
US-20050261302-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application HSD11B1, HSD17B1, HSD3B1 EPHX2 696/4885HSD11B1 1/4885CYP2C9 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.